The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
|Overal Status||Start Date||Phase||Study Type|
|Recruiting||November 28, 2017||N/A||Interventional|
Primary Outcome 1 - Measure: Minimal Dwell Time
Primary Outcome 1 - Time Frame: Day 1
- Diagnosis of bladder mass on office cystoscopy suspicious for malignancy, either newly
diagnosed or a recurrent tumor.
- Planned transurethral resection of bladder tumor in the operating room.
- Ability to give informed consent.
- Willing to spend time for the study
- Men or women (age 18 or older)
- Any racial or ethnic origin
- Nursing mother
- Diagnosis of porphyria
- Gross hematuria
- BCG immunotherapy or intravesical chemotherapy within the past 90 days
- Known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Edward M Messing, MD
Role: Principal Investigator
Affiliation: University of Rochester